Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15306236 | 1.00 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL15303706 | 0.92 | MTNR1A (0.34) | MTNR1AMTNR1B | |
| SCHEMBL15303513 | 0.85 | MTNR1A (0.35) | MTNR1AMTNR1B | |
| SCHEMBL21116386 | 0.85 | MTNR1A (0.35) | MTNR1AMTNR1B | |
| SCHEMBL15303511 | 0.85 | MTNR1A (0.35) | MTNR1AMTNR1B | |
| SCHEMBL20921338 | 0.82 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL9923849 | 0.82 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL19376290 | 0.81 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL19400272 | 0.80 | ALDH1A1 (0.39) | MTNR1AMTNR1B | |
| SCHEMBL9900825 | 0.80 | RAB9A (0.33) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | MTNR1A 2559/4885MTNR1B 2654/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | MTNR1A 2559/4885MTNR1B 2654/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | MTNR1A 2559/4885MTNR1B 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.